CUV — Clinuvel Pharmaceuticals Cashflow Statement
0.000.00%
- AU$579.43m
- AU$355.85m
- AU$95.02m
- 99
- 61
- 59
- 84
Annual cashflow statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.49 | 0.466 | 2.75 | 8.19 | 7.47 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 19.3 | 39.9 | 36.9 | 37.1 | 41.1 |
Capital Expenditures | -0.854 | -0.434 | -1.03 | -5.58 | -0.299 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -23.5 | -47.4 |
Purchase of Investments | |||||
Cash from Investing Activities | -0.854 | -0.434 | -1.03 | -29 | -47.7 |
Financing Cash Flow Items | -0.044 | 0 | 0 | — | -0.189 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -1.48 | -1.5 | -2.24 | -3.57 | -2.94 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 15.9 | 38.8 | 35.3 | 3.31 | -7.18 |